Detailed definition
Vasomotor symptoms (VMS) refer to the cluster of hot flashes (daytime episodes) and night sweats (nocturnal episodes) that share an underlying mechanism: estrogen-withdrawal-driven narrowing of the hypothalamic thermoneutral zone, with downstream signaling through KNDy neurons in the arcuate nucleus. The Study of Women's Health Across the Nation (SWAN) characterized four distinct VMS trajectories: early-onset (starting before perimenopause and often subsiding), late-onset (starting after the FMP), persistent (continuing throughout transition and well into postmenopause), and minimal (limited or absent symptoms). Median duration of moderate-to-severe VMS is 7.4 years. African American women, Hispanic women, women with higher BMI, smokers, and women with anxiety report longer and more severe VMS. VMS not only affect quality of life directly but are also associated with sleep disruption, depression, cognitive complaints, and emerging cardiovascular signals.
Why it matters in menopause
Treating VMS is not just about comfort. Severe VMS is associated with measurable cardiovascular and cognitive markers in observational data, suggesting it reflects underlying physiology that matters beyond the symptoms themselves. HRT remains the most effective treatment; fezolinetant offers a non-hormonal option that targets the same neural pathway.
Related terms
Sources
External references: Wikipedia.